AdvaMedDx Statement on President's FY 2014 Budget

You are here

AdvaMedDx Statement on President's FY 2014 Budget

April 10, 2013

WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) that represents companies that develop and manufacture medical diagnostic tests, released the following statement in response to the release of the President’s FY 2014 Budget:

“The President’s budget includes significant reductions to Medicare payments for clinical laboratory tests. Coming on top of recently enacted cuts to the Medicare Clinical Laboratory Fee Schedule, these further reductions would greatly undermine a critical area of health care. Innovation in diagnostic tests is driving key advances in patient care and outcomes, including personalized medicine. It is imperative that Medicare payments reflect the value of diagnostic tests and support continued innovation in this field.

“AdvaMedDx encourages new ways of recognizing the value of diagnostics in patient care, such as the Improving Diagnostics Innovation Act of 2012 (HR 6446) introduced by Reps. Peter J. Roskam (R-IL) and Leonard Lance (R-NJ) in the last Congress. We look forward to working with Congress and the Administration to identify better ways to value and reimburse for innovation in diagnostic tests.”

# # #

 AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad. 

For more information, please contact: Wanda Moebius @ 202-434-7240